BMRA - Biomerica, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.4500
+0.0500 (+2.08%)
As of 10:54AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close 2.4000
Open 2.4200
Bid 2.4500 x 800
Ask 2.4900 x 900
Day's Range 2.4000 - 2.4800
52 Week Range 1.6000 - 4.3300
Volume 1,046
Avg. Volume 26,582
Market Cap 23.685M
Beta (3Y Monthly) 2.98
PE Ratio (TTM) N/A
EPS (TTM) -0.2180
Earnings Date Apr 15, 2019 - Apr 19, 2019
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 6.25
Trade prices are not sourced from all markets
  • GlobeNewswire 2 days ago

    Biomerica Announces Third Quarter Financial Results

    Biomerica, Inc. (BMRA) today reported net sales of $4,034,822 for the nine months ending February 28, 2019, compared to $4,433,785 for the period ended February 28, 2018.  Sales for the three months ending February 28, 2019 were $1,261,161 compared to $1,375,666 for the period ended February 28, 2018.  In addition, the Company announced progress in both its InFoods® IBS clinical study and H. pylori study as well as the issuance of its first patent pertaining to the Company’s InFoods® family of products that are designed to allow for a revolutionary new treatment option for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. “We are very pleased that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Biomerica’s first U.S. patent pertaining to the Company’s InFoods® family of products.  The patent validates the unique InFoods product which is designed to allow physicians to offer new and better therapies to patients.

  • GlobeNewswire 10 days ago

    Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS)

    Biomerica, Inc. (BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biomerica’s first U.S. patent pertaining to the Company’s InFoods® family of products that allow for revolutionary new treatment option for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. Specifically, this allowed application (#15/526,240) contains numerous claims that broadly cover a product that enables physicians to identify patient specific foods (e.g.

  • ACCESSWIRE last month

    LD Micro Virtual Conference Is Live, March 12th and 13th

    LOS ANGELES, CA / ACCESSWIRE / March 12 , 2019 / LD Micro, a company that puts on conferences for micro-cap and small-cap companies will be hosting 46 companies on March 12th (that's today) and 13th, starting ...

  • What You Must Know About Biomerica, Inc.’s (NASDAQ:BMRA) Beta Value
    Simply Wall St. 2 months ago

    What You Must Know About Biomerica, Inc.’s (NASDAQ:BMRA) Beta Value

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Anyone researching Biomerica, Inc. (NASDAQ:BMRA) might want to consider theRead More...

  • GlobeNewswire 2 months ago

    Biomerica Announces Updates for H. Pylori Clinical Studies

    Based on recent discussions between Biomerica and the United States Food and Drug Administration (FDA) regarding the regulatory pathway for final FDA clearance of the Company’s H. pylori product, the Company needs less than 40 clinical trial patient samples in addition to the 210 samples already collected.  These final clinical patient samples are expected to be collected over the next few months, after which the Company will complete the remaining analytical and clinical agreement studies and prepare a submission to the FDA for 510(k) FDA clearance. Helicobacter pylori (H. pylori) infection is one of the most common, chronic, bacterial infections affecting humans.  Complications associated with H. pylori infections include ulcers, inflammation of the stomach lining and stomach cancer.  The diagnosis of H. pylori is important given that specific antibiotic treatment is highly effective in improving outcomes.

  • An Intrinsic Calculation For Biomerica, Inc. (NASDAQ:BMRA) Shows It’s 32.14% Undervalued
    Simply Wall St. 3 months ago

    An Intrinsic Calculation For Biomerica, Inc. (NASDAQ:BMRA) Shows It’s 32.14% Undervalued

    How far off is Biomerica, Inc. (NASDAQ:BMRA) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairly Read More...

  • Zacks Small Cap Research 3 months ago

    BMRA: Q2’19 Results: Asia Continues to Accelerate, Europe Rebounds, U.S. Still Weak But Could Return to Growth

    Results of an n=97 randomized, investigator-blinded food-exclusion study showed that Biomerica’s (BMRA) first-generation ELISA immunoglobulin G (IgG) antibody assay was able to significantly reduce ulcerative colitis symptoms and improve participants’ quality of life. In addition, this study assessed BMRA’s test in individuals with ulcerative colitis (UC) – while InFoods has been developed primarily to determine optimal food exclusion diets for people with irritable bowel syndrome.

  • GlobeNewswire 3 months ago

    Biomerica Announces Second Quarter Financial Results

    Biomerica, Inc. (BMRA) today reported net sales of $1,500,791 for the three months ended November 30, 2018, compared to $1,613,636  for the same period in the previous year.  Net sales were $2,773,661 for the six months ended November 30, 2018 compared to $3,058,119 for the same period in last year.  The Company ended the quarter with approximately $798,000 in backlog for open orders, which were not shipped as of November 30, 2018. Biomerica announced a net loss for the three months ended November 30, 2018 of $477,244, or $0.05 per share, versus a net loss of $268,661, or $0.03 per share, in the previous fiscal year during the same quarter.  The net loss for the six months ended November 30, 2018 was $928,984, or $0.10 per share, compared to net loss of $475,720, or $0.06 per share in the prior fiscal year.

  • GlobeNewswire 5 months ago

    Medline and Biomerica sign agreement for distribution of Biomerica’s colorectal screening test to help identify an early warning sign of colorectal cancer

    Biomerica, Inc. (BMRA) announced that is has signed a three year agreement with Medline Industries for the distribution of Biomerica’s EZ Detect™ colorectal disease screening test designed to help identify an early warning sign of colorectal cancer. The EZ Detect colorectal screening test is the simplest at home test to detect fecal occult (hidden) blood, an early warning sign of colorectal cancer. With over 18,000 employees worldwide, 1,600 direct sales reps and $10.2 billion in sales, Medline Industries is ranked 32 on the Forbes list of largest private companies.  Medline is the largest privately held manufacturer and distributor of medical supplies uniquely positioned to provide products, education and support across the continuum of care (from large healthcare systems and independent physician practices to home health patients and their families).

  • GlobeNewswire 5 months ago

    Consolidated Research: 2018 Summary Expectations for ProQR Therapeutics N.V, Biomerica, VEREIT, Apergy, Zendesk, and Arcus Biosciences — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Can We See Significant Insider Ownership On The Biomerica Inc (NASDAQ:BMRA) Share Register?
    Simply Wall St. 5 months ago

    Can We See Significant Insider Ownership On The Biomerica Inc (NASDAQ:BMRA) Share Register?

    Every investor in Biomerica Inc (NASDAQ:BMRA) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to Read More...

  • GlobeNewswire 5 months ago

    Biomerica’s Diagnostic Product Guides Exclusionary Diet Treatment to Successfully Alleviate Symptoms of Ulcerative Colitis (UC) in Prospective Clinical Stud

    Eliminating positive foods identified by Biomerica’s diagnostic product showed statistically significant improvements (p

  • Zacks Small Cap Research 6 months ago

    BMRA: Q1 2019: Asia Strong, Europe & U.S. Weak. Revenue up 13% QoQ But Down 12% yoy. Expense Control Minimizes Op Loss.

    Biomerica (BMRA) reported financial results for their fiscal 2019 first quarter ending August 31, 2018. The weakness related almost entirely to Europe and the U.S., which were both down double-digit percentages from the year-earlier period. Fortunately Asia, which accounts for ~50% of total revenue saw solid gains from both comparable periods, limiting the yoy total revenue slide and pushing it into positive territory sequentially.

  • Is Biomerica Inc (NASDAQ:BMRA) A Financially Sound Company?
    Simply Wall St. 7 months ago

    Is Biomerica Inc (NASDAQ:BMRA) A Financially Sound Company?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Biomerica Inc (NASDAQ:BMRA), as the company does not have to adhere to strict debt covenants. However, it also faces higher Read More...

  • Zacks Small Cap Research 7 months ago

    BMRA: Legacy Biz Slows in Q4. Operational Highlights Include InFoods Enrolling, Ex-Walgreens CMO Joins SAB (and we’re intrigued)

    Biomerica (BMRA) reported financial results for their fiscal 2018 fourth quarter ending May 31, 2018. While our model had revenue inching up 6% for the full-year reflecting an expectation that rebounding sales in Asia would more than offset ongoing softness in both Europe and the U.S., that was far from the case. Instead, the nearly across-the-board (Latin America was the sole bright spot) weakness in Q4, which most notably included a 42% yoy contraction in Asia, resulted in annual sales falling almost 4%.

  • When Can We Expect A Profit From Biomerica Inc (NASDAQ:BMRA)?
    Simply Wall St. 11 months ago

    When Can We Expect A Profit From Biomerica Inc (NASDAQ:BMRA)?

    Biomerica Inc’s (NASDAQ:BMRA): Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. WithRead More...

  • Should You Be Concerned About Biomerica Inc’s (NASDAQ:BMRA) Shareholders?
    Simply Wall St. 11 months ago

    Should You Be Concerned About Biomerica Inc’s (NASDAQ:BMRA) Shareholders?

    Today, I will be analyzing Biomerica Inc’s (NASDAQ:BMRA) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure of a company has been found to affect shareRead More...

  • Zacks Small Cap Research last year

    BMRA: Q3 2018 Results: Asia Remains Strong While U.S., Europe Slip. Encouraged By Robustness of InFoods Study Design

    Biomerica (BMRA) reported financial results for their fiscal 2018 third quarter ending February 28, 2018. Revenue, down 8% yoy and 15% qoq, was softer than we were expecting with both Europe and U.S. sales contributing to the miss. • Fiscal Q3 has historically been a relatively strong quarter for BMRA’s U.S. business – and while that proved to be true as compared to the first two quarters of 2018, on a prior years’ basis, domestic sales were relatively very weak – in fact, the lowest Q3 U.S. number since at least 2009.